News & Trends
Novel Peptide Bioscience Co., Ltd. Officially Starts its Phase III Clinical Trial of Project NHT210118
On February 4, 2021 (BJT), the Project "NHT210118" with the drug name "Therapeutic (Synthetic Peptide) Hepatitis B Vaccine" was officially started.
The NMPA Phase III clinical trial approval (approval No.: 2018L02469) was obtained on May 14, 2018 for Project NHT210118, and the transfer was completed by Mendel (a wholly-owned subsidiary of Novel Peptide) on October 21, 2020. After half a year of preparation, the Phase III Clinical Study Protocol of Project NHT210118 was finalized on February 4, 2021, which marked the official start of the Phase III clinical trial of Project NHT210118. The R&D team of Novel Peptide showed a positive expectation for Project NHT210118 and thought the Project was expected to be completed within 3 years.
